Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interleukin-1 receptor antagonist

W P Arend1

  • 1Department of Medicine, University of Colorado Health Sciences Center, Denver 80262.

Advances in Immunology
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Interleukin-1 receptor antagonist (IL-1ra) blocks IL-1 effects by competitively inhibiting receptor binding. This cytokine antagonist shows potential therapeutic benefits in inflammatory conditions like sepsis and arthritis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The role of interleukin-1 receptor antagonist in the prevention and treatment of disease.

Modern rheumatology·2014
Same author

Fate of preformed immune complexes in rabbits and rhesus monkeys.

The Journal of experimental medicine·2009
Same author

Complement activation pathways in murine immune complex-induced arthritis and in C3a and C5a generation in vitro.

Clinical and experimental immunology·2009
Same author

Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody.

Arthritis and rheumatism·2004
Same author

The innate immune system in rheumatoid arthritis.

Arthritis and rheumatism·2001
Same author

May 2001: 32 year old female with dural mass encircling cervical spinal cord.

Brain pathology (Zurich, Switzerland)·2001
Same journal

The roles and diversity of alarmins in the mucosae.

Advances in immunology·2026
Same journal

Principles of resident tissue macrophages revealed by the eye.

Advances in immunology·2026
Same journal

Beyond suppression: Treg specialization in infection and tissue repair.

Advances in immunology·2026
Same journal

Ontogeny and function of microglia and nerve-associated macrophages.

Advances in immunology·2025
Same journal

Neuroimmunology beyond the CNS: Nerve-macrophage interactions in peripheral tissues.

Advances in immunology·2025
Same journal

Modulation of humoral immunity by γδ T cells: A potential adjuvant strategy for vaccination.

Advances in immunology·2025
See all related articles

Area of Science:

  • Immunology
  • Molecular Biology
  • Genetics

Background:

  • Interleukin-1 receptor antagonist (IL-1ra) is the first identified naturally occurring receptor antagonist for any cytokine.
  • IL-1ra shares sequence homology, gene structure, and chromosomal localization with IL-1 beta and IL-1 alpha, classifying it within the IL-1 family.
  • Two variants, secretory (sIL-1ra) and intracellular (icIL-1ra), exist, produced by various cell types including immune cells and epithelial cells.

Purpose of the Study:

  • To characterize the molecular properties and biological activity of IL-1ra.
  • To investigate the binding interactions of IL-1ra with IL-1 receptors (IL-1RIs and IL-1RIIs).
  • To explore the potential therapeutic applications of IL-1ra in inflammatory diseases.

Main Methods:

  • Analysis of amino acid sequence homology, gene structure, and gene localization to establish IL-1ra's family membership.

Related Experiment Videos

  • Investigation of IL-1ra binding affinity to cell surface and soluble IL-1 receptors.
  • Evaluation of IL-1ra's efficacy in blocking IL-1 mediated responses in animal models and preliminary human clinical trials.

    • Main Results:

    • IL-1ra binds to both IL-1RIs and IL-1RIIs, with a significantly higher affinity for IL-1RIs.
    • IL-1ra competitively inhibits IL-1 alpha and IL-1 beta binding to receptors without triggering intracellular responses.
    • A substantial molar excess of IL-1ra over IL-1 is required to inhibit biological responses.
    • IL-1ra demonstrated efficacy in blocking IL-1 effects in animal models of septic shock, inflammatory arthritis, GVHD, and IBD.
    • Preliminary human trials suggest potential efficacy in sepsis syndrome, rheumatoid arthritis, and GVHD.

    Conclusions:

    • IL-1ra acts as a competitive antagonist of IL-1, modulating inflammatory responses.
    • The distinct binding characteristics and lack of intracellular signaling induction differentiate IL-1ra from IL-1.
    • IL-1ra holds promise as a therapeutic agent for various IL-1-mediated inflammatory conditions.